Muling Mao

Learn More
3533 Background: Circulating angiogenic factors have been previously shown to be altered in patients (pts) with mCRC on bevacizumab (BV)-containing regimens. However, a systematic evaluation of alterations in levels of the VEGF family of ligands may provide insights into resistance mechanisms. METHODS 42 patients (pts) with mCRC were treated on a single(More)
  • 1